Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En mulighetsprøve for å finne ut om Linvoseltamab er trygt og godt tolerert, og hvor godt det fungerer hos deltakere med nylig diagnostisert myelomatose som ikke allerede har mottatt behandling. (LINKER-MM4)

5. november 2026 oppdatert av: Regeneron Pharmaceuticals

Fase 1/2-studie av Linvoseltamab (Anti-BCMA X Anti-CD3 bispesifikt antistoff) hos tidligere ubehandlede pasienter med symptomatisk myelomatose

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible).

The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM.

This study consists of 2 phases:

  • In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2.
  • In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug.
  • In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM.

The study is looking at several research questions, including:

  • What side effects may happen from taking linvoseltamab?
  • What the right dosing regimen is for linvoseltamab?
  • How many participants treated with linvoseltamab have improvement of their disease and for how long?
  • The effects of linvoseltamab study treatment before and after transplant
  • How much linvoseltamab is in the blood at different times?
  • Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).

Studieoversikt

Status

Aktiv, ikke rekrutterende

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

148

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Los Angeles, California, Forente stater, 90095
        • University of California Los Angeles (UCLA)
      • Orange, California, Forente stater, 92868
        • UC Irvine Health
    • Colorado
      • Denver, Colorado, Forente stater, 80218
        • Colorado Blood Cancer Institute/SCRI
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40207
        • Norton Cancer Institute
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
        • Karmanos Cancer Institute
    • New Jersey
      • New Brunswick, New Jersey, Forente stater, 08901
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Mineola, New York, Forente stater, 11501
        • Perlmutter Cancer Center at NYU Langone Hospital - Long Island
      • New York, New York, Forente stater, 10016
        • Perlmutter Cancer Center
      • New York, New York, Forente stater, 10032
        • Columbia University _ New York Presbyterian
      • Stony Brook, New York, Forente stater, 11794
        • Stony Brook University Hospital
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28204
        • Levine Cancer Institute
      • Durham, North Carolina, Forente stater, 27705
        • Duke University Health System (DUHS)
    • Texas
      • Houston, Texas, Forente stater, 77030
        • The University of Texas MD Anderson Cancer Center
      • Lille, Frankrike, 59000
        • CHU De Lille
      • Montpellier, Frankrike, 342950
        • Centre Hospitalier Universitaire (CHU) Montpellier
      • Paris, Frankrike, 75010
        • Hopital Saint Louis
      • Paris, Frankrike, 75651
        • University Hospitals Pitie Salpetriere - Charles Foix
    • Vienne
      • Poitiers, Vienne, Frankrike, 86021
        • Centre Hospitalier Universitaire (CHU) de Poitiers
    • Île-de-France Region
      • Antony, Île-de-France Region, Frankrike, 92160
        • Hopital Prive d'Antony
      • Paris, Île-de-France Region, Frankrike, 75015
        • Hopital Necker
      • Villejuif, Île-de-France Region, Frankrike, 94800
        • Gustave Roussy
      • Barcelona, Spania, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Spania, 08908
        • Institut Catala dOncologia (ICO Hospitalet)
      • Madrid, Spania, 28027
        • Clinica Universidad de Navarra - Madrid
      • Madrid, Spania, 28006
        • Universitary Hospital La Princesa
      • Salamanca, Spania, 37007
        • Hospital Universitario de Salamanca
      • Valencia, Spania, 46026
        • Hospital Universitari i Politecnic La Fe
    • Barcelona
      • Badalona, Barcelona, Spania, 08916
        • Hospital Germans Trias i Pujol
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spania, 28223
        • Hospital Universitario Quiron Salud Madrid
    • Navarre
      • Pamplona, Navarre, Spania, 31008
        • Clinica Universidad de Navarra
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spania, 33011
        • Hospital Universitario Central de Asturias
    • Valencia
      • Alicante, Valencia, Spania, 03010
        • Hospital General Universitario Doctor Balmis Alicante

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  2. Confirmed diagnosis of symptomatic Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria, as described in the protocol
  3. Response-evaluable myeloma, according to the 2016 IMWG response criteria, as defined in the protocol
  4. No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol
  5. Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol
  6. Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.

Key Exclusion Criteria:

  1. Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis
  2. Known Central Nervous System (CNS) involvement with MM, known or suspected Progressive Multifocal Leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment
  3. Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy
  4. Diagnosis of non-secretory MM, active plasma cell leukemia primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (Plasma cell dyscrasia with polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 1 cohorts

Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve.

Linvoseltamab will be administered by intravenous (IV) infusion

Andre navn:
  • REGN5458
  • Lynozyfic ™
Eksperimentell: Phase 2 - transplant ineligible cohort

Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol.

Linvoseltamab will be administered by intravenous (IV) infusion

Andre navn:
  • REGN5458
  • Lynozyfic ™
Eksperimentell: Phase 2 - transplant eligible cohort

Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol

Linvoseltamab will be administered by intravenous (IV) infusion

Andre navn:
  • REGN5458
  • Lynozyfic ™

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Dose-Limiting Toxicities (DLTs)
Tidsramme: End of the Observation period; up to day 28

Phase 1

End of the Observation period; up to day 28
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Severity of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of Adverse Events of Special Interest (AESIs)
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Severity of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
Tidsramme: Up to 5 years

Phase 2

Up to 5 years
Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
Tidsramme: Up to 5 years

Phase 2 Transplant-eligible cohort

Up to 5 years
Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
Tidsramme: Up to 5 years

Phase 2 Transplant-eligible cohort

Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
Tidsramme: Up to 5 years

Phase 2 Transplant-ineligible cohort

Up to 5 years
Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
Tidsramme: Up to 5 years

Phase 2 Transplant ineligible cohort

Up to 5 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Concentrations of Linvoseltamab in serum
Tidsramme: Post-Last Linvoseltamab Dose, up to 12 weeks

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 12 weeks
Concentrations of total soluble B-Cell Maturation Antigen (BCMA)
Tidsramme: Post-Last Linvoseltamab Dose, up to 12 weeks

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 12 weeks
Incidence of Anti-Drug Antibodies (ADAs) to Linvoseltamab
Tidsramme: Post-Last Linvoseltamab Dose, up to 30 days

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 30 days
Magnitude of ADAs to Linvoseltamab
Tidsramme: Post-Last Linvoseltamab Dose, up to 30 days

Phases 1 and 2

Post-Last Linvoseltamab Dose, up to 30 days
Objective Response Rate (ORR) measured using the IMWG criteria
Tidsramme: Up to 5 years

Phase 1

Up to 5 years
Duration Of Response (DOR) measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Progression-Free Survival (PFS) measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 1

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Severity of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Severity of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Up to 5 years

Phase 2

Up to 5 years
MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Time To Response (TTR) as measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
ORR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
MRD-negative status by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
DOR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
TTR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
PFS by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days

Phase 2

Post-Last Linvoseltamab Dose, up to 90 days
Incidence of MRD-negative status
Tidsramme: Up to 5 years

Phase 2

Up to 5 years
Cluster of Differentiation 34+ (CD34+) stem cell yield
Tidsramme: At cycle 4 of induction (each cycle is 28 days long)

Phase 2 Transplant-eligible cohort

At cycle 4 of induction (each cycle is 28 days long)
Time to neutrophil engraftment
Tidsramme: Up to 100 days post-transplant

Phase 2 Transplant-eligible cohort

Up to 100 days post-transplant
Time to platelet engraftment
Tidsramme: Up to 100 days post-transplant

Phase 2 Transplant-eligible cohort

Up to 100 days post-transplant
PFS after ASCT followed by 3 cycles of linvoseltamab
Tidsramme: Up to 5 years

Phase 2 Transplant-eligible cohort

Up to 5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. desember 2023

Primær fullføring (Antatt)

2. november 2035

Studiet fullført (Antatt)

2. november 2035

Datoer for studieregistrering

Først innsendt

12. april 2023

Først innsendt som oppfylte QC-kriteriene

12. april 2023

Først lagt ut (Faktiske)

25. april 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD-delingstidsramme

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Tilgangskriterier for IPD-deling

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere